Found 1429 clinical trials
27 feb-
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 27 Feb, 2023
- 1 location
VitaFlow II Transcatheter Aortic Valve System Pre-market Trial
This is a pre-market clinical investigation aiming to evaluate the safety and effectiveness of Microport CardioFlow VitaFlow II Transcatheter Aortic Valve System for the treatment of severe aortic stenosis.
- 0 views
- 05 Aug, 2020
Supra-Annular vs. Annular ValvEs for Small Annuli
Open-label, prospective randomized comparison of Supra-annular valves (Medtronic Evolut Pro) vs. annular valves (Edwards Sapien Ultra) for small annuli (23 mm)
- 0 views
- 16 Feb, 2024
- 1 location
Assessment of Paravalvular Leak After TAVI by Hemodynamic Measurements and Cardiac MRI
Prospective data for self-expanding devices are required to compare the extent of paravalvular leakage as a result of device design. Grading paravalvular leakage after TAVI is difficult. Echocardiography and angiography systematically underestimate paravalvular leakage (PVL) as compared to cardiac MRI.
- 0 views
- 16 Feb, 2024
- 1 location
Role of CEUS as a Secondary Diagnostic Modality
To determine the role of contrast-enhanced ultrasound (CEUS) as a second-line imaging modality after gadoxetate-enhanced MRI (Gd-EOB-MRI) for identifying hepatocellular carcinoma (HCC) among at-risks observations.
- 0 views
- 05 Aug, 2020
As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period
This study will evaluate the efficacy of as-needed Budesonide/formoterol Turbuhaler 160/4.5 g/d in the period of step down in well controlled asthmatic patient comparing with standard maintenance therapy in step-2 management in asthma guildeline which is low dose inhaled corticosteroid.
- 0 views
- 16 Feb, 2024
- 1 location
Cortico-Spinal tDCS as Rehabilitative Intervention in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which is a group of neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body. The disorder causes muscle weakness and atrophy throughout the body due to the degeneration of the upper and lower motor …
- 0 views
- 16 Feb, 2024
- 1 location
Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
The aim of the single-arm, open-label, phase II clinical trial is to assess efficacy and safety of lenvatinib as a preoperative conversion therapy in patients with potentially resectable HCC. Investigator hypothesized that lenvatinib may be an effective conversion treatment for HCC, and preoperative treatment with lenvatinib can improve resectability in …
- 0 views
- 16 Feb, 2024
- 4 locations
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus
A recent randomized trial has proved the efficacy of Rituximab, a monoclonal anti-CD20 antibody against B-lymphocytes, as an efficacious therapy for pemphigus. Early use of rituximab was associated with better clinical outcomes, hence combination treatment of rituximab and intravenous immunoglobulins (IVIG) has shown to be effective for refractory pemphigus cases …
- 0 views
- 16 Feb, 2024
- 1 location